FINWIRES · TerminalLIVE
FINWIRES

Top Midday Gainers

By

Napo Pharmaceuticals, part of Jaguar Health (JAGX), said Tuesday the US Food and Drug Administration has granted a waiver of the fee associated with the Prescription Drug User Fee Act for Mytesi for fiscal 2027.

Shares surged 350% as intraday trading volume catapulted to over 9.8 million from a daily average of about 29,000.

Omeros (OMER) shares jumped 13% amid heavy trading after Cantor Fitzgerald upgraded the stock to overweight from neutral.

Over 2.78 million shares traded intraday versus a daily average of roughly 1.94 million.

Silvia (SVIA), formerly ProCap Financial, said its corporate name change is effective, and its common stock and warrants began trading on Tuesday on the Nasdaq Global Market.

Shares climbed 15% as intraday trading volume surged to over 2.5 million.

Price: $12.19, Change: $+9.52, Percent Change: +356.37%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA